Literature DB >> 16962067

Critical role of the FERM domain in Pyk2 stimulated glioma cell migration.

Christopher A Lipinski1, Nhan L Tran, Andrea Dooley, Yuan-Ping Pang, Carole Rohl, Jean Kloss, Zhongbo Yang, Wendy McDonough, David Craig, Michael E Berens, Joseph C Loftus.   

Abstract

The strong tendency of malignant glioma cells to invade locally into surrounding normal brain precludes effective surgical resection, reduces the efficacy of radiotherapy, and is associated with increased resistance to chemotherapy regimens. We report that the N-terminal FERM domain of Pyk2 regulates its promigratory function. A 3-dimensional model of the Pyk2 FERM domain was generated and mutagenesis studies identified residues essential for Pyk2 promigratory function. Model-based targeted mutations within the FERM domain decreased Pyk2 phosphorylation and reduced the capacity of Pyk2 to stimulate glioma cell migration but did not significantly alter the intracellular distribution of Pyk2. Expression of autonomous Pyk2 FERM domain fragments containing analogous mutations exhibited reduced capacity to inhibit glioma cell migration and Pyk2 phosphorylation relative to expression of an autonomous wild type FERM domain fragment. These results indicate that the FERM domain plays an important role in regulating the functional competency of Pyk2 as a promigratory factor in glioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962067     DOI: 10.1016/j.bbrc.2006.08.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.

Authors:  Ssang-Taek Lim; Nichol L G Miller; Ju-Ock Nam; Xiao Lei Chen; Yangmi Lim; David D Schlaepfer
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

2.  The nonreceptor protein tyrosine kinase Pyk2 promotes the turnover of monocytes at steady state.

Authors:  Ryan A Llewellyn; Keena S Thomas; Michael F Gutknecht; Amy H Bouton
Journal:  J Leukoc Biol       Date:  2017-07-28       Impact factor: 4.962

3.  Dynamin and PTP-PEST cooperatively regulate Pyk2 dephosphorylation in osteoclasts.

Authors:  Pierre P Eleniste; Liping Du; Mahesh Shivanna; Angela Bruzzaniti
Journal:  Int J Biochem Cell Biol       Date:  2012-02-08       Impact factor: 5.085

Review 4.  The FERM domain: organizing the structure and function of FAK.

Authors:  Margaret C Frame; Hitesh Patel; Bryan Serrels; Daniel Lietha; Michael J Eck
Journal:  Nat Rev Mol Cell Biol       Date:  2010-11       Impact factor: 94.444

5.  The Pyk2 FERM regulates Pyk2 complex formation and phosphorylation.

Authors:  Daniel Riggs; Zhongbo Yang; Jean Kloss; Joseph C Loftus
Journal:  Cell Signal       Date:  2010-09-16       Impact factor: 4.315

Review 6.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

7.  Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2.

Authors:  Nathalie Meurice; Lei Wang; Christopher A Lipinski; Zhongbo Yang; Christopher Hulme; Joseph C Loftus
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  Differential effects of Pyk2 and FAK on the hypertrophic response of cardiac myocytes.

Authors:  Emmanuel B Menashi; Joseph C Loftus
Journal:  Cell Tissue Res       Date:  2009-05-12       Impact factor: 5.249

9.  The Pyk2 FERM domain as a target to inhibit glioma migration.

Authors:  Joseph C Loftus; Zhongbo Yang; Nhan L Tran; Jean Kloss; Carole Viso; Michael E Berens; Christopher A Lipinski
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

10.  Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts.

Authors:  Christopher A Lipinski; Nhan L Tran; Carole Viso; Jean Kloss; Zhongbo Yang; Michael E Berens; Joseph C Loftus
Journal:  J Neurooncol       Date:  2008-07-22       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.